BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30527396)

  • 1. [Melanoma update].
    Longvert C; Saiag P
    Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in malignant melanoma.
    Atkinson V
    Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [What's new in skin cancers?].
    Jouary T
    Ann Dermatol Venereol; 2014 Dec; 141 Suppl 4():S630-42. PubMed ID: 25539755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
    Johnson DB; Sosman JA
    JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Melanoma, from diagnosis to treatment].
    Baroudjian B; Pagès C; Lebbé C
    Rev Infirm; 2016 Mar; (219):16-8. PubMed ID: 26944639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy for malignant melanoma].
    Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
    Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
    Zhu Z; Liu W; Gotlieb V
    Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in immunotherapy for metastatic melanoma].
    Oláh J
    Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel treatment options must prove their effectiveness: targeted treatment and immunotherapy for locally advanced melanoma].
    van Thienen JV
    Ned Tijdschr Geneeskd; 2018 Jun; 162():. PubMed ID: 30040280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.
    Keung EZ; Gershenwald JE
    J Natl Cancer Inst; 2020 Sep; 112(9):875-885. PubMed ID: 32061122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in systemic treatment of melanoma.
    Eggermont AM
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii339-44. PubMed ID: 20943639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State of melanoma: an historic overview of a field in transition.
    Gorantla VC; Kirkwood JM
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):415-35. PubMed ID: 24880939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
    Swe T; Kim KB
    Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
    Dummer R; Schadendorf D; Ascierto PA; Larkin J; Lebbé C; Hauschild A
    Melanoma Res; 2015 Dec; 25(6):461-9. PubMed ID: 26426764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Overview of the Changing Landscape of Treatment for Advanced Melanoma.
    Lee CS; Thomas CM; Ng KE
    Pharmacotherapy; 2017 Mar; 37(3):319-333. PubMed ID: 28052356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic treatment of inoperable metastasized malignant melanoma].
    Gutzmer R; Rauschenberg R; Meier F
    Hautarzt; 2016 Jul; 67(7):529-35. PubMed ID: 27164828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of targeted therapy for melanoma in the immunotherapy era.
    Sullivan RJ
    Semin Cutan Med Surg; 2018 Jun; 37(2):112-119. PubMed ID: 30040088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
    Melis C; Rogiers A; Bechter O; van den Oord JJ
    Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.